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ABSTRACT
Regulatory T (Treg) cells and host antigen-presenting cells (APCs) have been implicated in graft-versus-host
disease (GVHD) and the graft-versus-leukemia (GVL) effect after donor lymphocyte infusion (DLI), but their
relative contributions remain unclear in early versus long-term complete donor or mixed murine allogeneic
hematopoietic stem cell (HSC) chimeras. We have previously demonstrated that donor HSC-derived Thy1
Treg cells, consisting primarily of CD4
CD25 cells, play an important role in the suppression of graft-versus-
host (GVH) reactivity when DLI is given to complete donor chimeras 28 days after HSC transplantation. Data
presented here demonstrate that protection against GVHD exerted by Thy1 Treg cells is less evident with
time and eventually is not required in long-term complete donor chimeras because of an absence of host-type
APCs to activate alloreactive T cells. Lethal GVHD was observed when Thy1 Treg cells were depleted from
complete donor chimeras given by DLI at day 28, 35, or 42; however, Treg cell depletion and DLI at day 70 no
longer induced GVHD-associated mortality. Moreover, the failure of DLI to induce GVHD with Treg
depletion correlated with a loss of the DLI-induced GVL effect in long-term (day 100) complete donor
chimeras. In contrast to the results from complete donor chimeras, GVL reactivity in day 100 mixed chimeras
was robust after DLI. Loss of a DLI-induced GVL effect in long-term complete donor chimeras was attributed
to the absence of host APCs because the infusion of exogenous host-type dendritic cells partially restored both
DLI-induced GVL and GVH reactions in day 100 complete donor chimeras. The GVL and GVH reactions
restored by infusion of host dendritic cells in day 100 complete donor chimeras were at least partially regulated
by Treg cells because transient depletion of CD25
 cells increased both the GVL effect and the severity of
GVHD after DLI. Taken together, these data suggest that Treg cells can regulate DLI-induced GVL and GVH
reactions in both early and long-term complete donor chimeras, and a state of mixed chimerism is superior to
complete donor chimerism because host-type APCs facilitate a DLI-induced GVL effect without severe GVHD.
© 2006 American Society for Blood and Marrow Transplantation
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bNTRODUCTION
Donor lymphocyte infusion (DLI) has become a
tandard form of immunotherapy for treating leuke-
ia relapse after hematopoietic stem cell transplanta-
ion (HSCT) in humans. It is particularly effective for
nducing remission in chronic myeloid leukemia pa- c
B&MTients but is less beneﬁcial for other types of leukemia
1-5]. The ability of immune cells in the DLI inocu-
um to react against leukemia cells is referred to as the
raft-versus-leukemia (GVL) effect [2]. DLI has also
een used to facilitate immune reconstitution, treat
hronic viral infections such as Epstein-Barr virus and
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3ytomegalovirus, correct immunodeﬁciencies, and in-
rease donor chimerism in mixed donor/host chimeric
nimals or humans [3].
Graft-versus-host disease (GVHD), a major com-
lication of DLI therapy, typically correlates with
esirable GVL reactivity and response rates [1-5].
ence, common target antigens (Ags) and/or effector
ells have been suspected in the processes of GVHD
nd GVL after DLI, although the GVL effect has
een separable from GVHD in experimental animal
odels [6-9]. In a large retrospective analysis, acute or
hronic GVHD occurred in up to 60% of DLI-treated
atients and accounted for 10% of deaths in these pa-
ients [4]. More than 90% of complete responders de-
eloped acute GVHD, and 88% of responders devel-
ped chronic GVHD [4]. In contrast, remissions have
een rarely observed in patients without GVHD after
LI. Fortunately, GVHD in this setting has fre-
uently been mild to moderate and responsive to im-
unosuppressive therapy. Moreover, adoption of a dose-
scalation DLI strategy has been shown to decrease the
isk for developing life-threatening GVHD [4].
DLI has allowed for the infusion of donor T cells
t numbers that would typically induce lethal GVHD
f given at the time of HSCT. Elucidation of the
mmunologic mechanisms involved in regulating graft-
ersus-host (GVH) reactivity is needed to optimize
linical usage for DLI-based immunotherapy. As pos-
ible mechanisms, ﬁndings from clinical and experimen-
al studies have implicated avoidance of the cytokine
torm initiated by pretransplantation conditioning, de-
reased numbers of host Ag-presenting cells (APCs) at
he time of DLI, and development of regulatory T
Treg) cells [10-13], but APC and Treg dynamics (eg,
hort-, intermediate-, or long-term after transplanta-
ion) and their relative contributions at each stage
ave not been fully addressed. Recently, diminished
LI-induced GVL reactivity was seen in long-term
ajor histocompatibility complex (MHC)–matched or
ismatched complete hematopoietic stem cell (HSC)
himeras [14,15]. Similar ﬁndings have also been
ade in long-term MHC-mismatched chimeras that
ad converted from mixed to complete donor chimer-
sm after an earlier DLI [16]. In this study, MHC-
ismatched C57BL/6 (B6)–into-AKR complete do-
or chimeras and B6-into-AKR mixed donor/host
himeras were used to address Treg cell dynamics and
LI-induced GVL/GVH effects in early versus long-
erm HSC chimeras. First, we examined DLI-induced
VHD at several time points after HSCT (eg, days
8, 35, 42, 49, and 70) and the inﬂuence of Thy1
reg cell depletion on GVHD at each time point.
econd, we compared DLI-induced GVL in early (day
8) versus late (day 100) complete donor chimeras.
hird, we examined GVL reactivity in long-term
omplete donor and mixed donor/host chimeras. Fi-
ally, we investigated the effect of in vivo CD25 Treg r
98ell depletion on DLI-induced GVL/GVHD and
hether host-type APCs, in the form of dendritic cells
DCs), given to long-term complete donor chimeras
ould inﬂuence GVL and GVH reactions.
ATERIALS AND METHODS
ice
AKR/J (H-2k, Thy1.1), AKR/Cum (H-2k, Thy1.2),
57BL/6 (B6; H-2b, Thy1.2), and B6.PL-Thy1a/Cy
B6.PL; H-2b, Thy1.1) mice were purchased from the
ackson Laboratory (Bar Harbor, ME) and housed in
he Biomedical Resource Center at the Medical Col-
ege of Wisconsin (Milwaukee, WI).
eagents and Monoclonal Antibodies
The following monoclonal antibodies (mAbs) were
urchased from BD Pharmingen (San Diego, CA): ﬂu-
rescein isothiocyanate (FITC)–conjugated anti–H-2Kb
clone AF6-88.5), FITC–anti-CD11c (clone HL3), phyco-
rythrin (PE)–conjugated anti-CD3 (clone 145-2C11),
E–anti-CD25 (clone PC61), PE–anti-CD45R/B220
clone RA3-6B2), PE–anti-CD11b (clone M1/70),
E–anti-Ly6G/6C (clone RB6-8C5), allophycocya-
in-conjugated anti-CD4 (clone RM4-5), and PE–
y5–anti-CD8a (clone 53-6.7). In vivo–depleting an-
i-CD25 (clone PC61) and anti-Thy1.2 (clone 53-2.1)
Abs were produced from hybridoma cells obtained
rom the American Type Culture Collection (Bethesda,
D). These mAbs were produced in our laboratory by
sing a Vivascience bioreactor system (Hanover, Ger-
any). Rabbit complement was purchased from Cedar-
ane Laboratories Ltd. (Hornby, Ontario, Canada). An-
i-CD11c (N418)–conjugated immunomagnetic
eads were purchased from Miltenyi Biotec Inc. (Au-
urn, CA). Collagenase D was obtained from Roche
pplied Sciences (Indianapolis, IN). Bovine serum
lbumin and 2-mercaptoethanol were obtained from
igma (St. Louis, MO). Fetal bovine serum, phos-
hate-buffered saline, high-glucose Dulbecco’s mod-
ﬁed eagle medium, 4-(2-hydroxyethyl)-1-pipera-
ineethanesulfonic acid buffer, sodium pyruvate,
-glutamine, l-arginine, l-asparagine, folic acid, non-
ssential amino acids, and penicillin/streptomycin
ere obtained from Invitrogen (Carlsbad, CA).
n Vitro Isolation of DCs
Spleens harvested from AKR mice were digested
ith collagenase D (1 mg/mL) for 45 minutes at 37°C
n a 5% carbon dioxide incubator. The splenocytes
ere then washed, incubated with anti-CD11c–con-
ugated immunomagnetic beads for 15 minutes at 4°C,
nd puriﬁed by positive selection with an automated
iltenyi Biotec immunomagnetic cell sorter. The pu-ity of CD11c DCs was 98%.
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GVL and GVH Reactions After DLI
Bstablishment of Complete Donor and Mixed
onor/Host HSC Chimeras
To establish complete donor HSC chimeras, AKR/J
osts were lethally irradiated with 1100 cGy 1 day before
SC. Fresh bone marrow (BM) cells harvested from B6
onors were depleted of mature T cells in vitro by using
nti-Thy1.2 mAb and rabbit complement. A total of
07 T cell–depleted nucleated BM cells were given
ntravenously (IV) to each recipient via the tail veins.
o establish mixed donor/host HSCT chimeras,
KR/Cum mice were lethally irradiated with 1100
Gy 1 day before HSCT, and a single intraperitoneal
IP) injection of anti-Thy1.2 mAb (500 g) was given
n the day of HSCT to prevent graft rejection. Fresh
M cells harvested from B6 and AKR/Cum donor
ice were mixed at a donor-host ratio of 3:1, and a
otal of 107 non–T cell–depleted BM cells (ie, 7.5 
06 from B6 and 2.5  106 from AKR/Cum) were
njected IV. Levels of donor HSC engraftment were
onﬁrmed 3 weeks after transplantation by ﬂow cyto-
etric analysis of peripheral blood leukocytes by using
he following cell-surface markers: FITC–anti–H-2Kb,
ITC–anti–H-2Kk, PE–anti-CD3, PE–anti-B220, PE–
nti–Mac-1, PE–anti-Ly6G/6C, PE–Cy5–anti-CD8,
nd allophycocyanin–anti-CD4.
LI and Leukemia Challenge
In all DLI studies, 3  107 splenocytes isolated
rom B6.PL mice (Thy1.1) were administered IV at
arious time points after HSCT (days 28, 35, 42, 49,
0, and 100) to complete donor chimeras or to long-
erm mixed chimeras (day 100). Some DLI recipients
ere injected IP with anti-Thy1.2 mAb (500 g) on
he day of DLI to deplete donor BM-derived Thy1.2
cells in vivo. Treatment with anti-Thy1.2 mAb
esults in98% depletion of Thy1.2 cells (Figure 1).
ther recipients were treated IP with anti-CD25 mAb
days (500 g at day 93) and 4 days (250 g at day 96)
efore DLI to deplete CD25 cells in vivo. The op-
imal dose of anti-CD25 mAb needed to achieve max-
mal depletion of CD25 T cells was determined in
reliminary experiments (data not shown). In some
ay 28 or day 100 complete donor HSC chimeras,
.5  106 or 5  106 puriﬁed AKR DCs were infused
lone or together with a DLI. To assess GVL reac-
ivity, mice were challenged IV with 103 AKR-derived
2 leukemia/lymphoma cells 1 week after DLI (ie,
ay 35 or day 107). The origin and characteristics of
he M2 tumor, a T-cell leukemia/lymphoma that
pontaneously arose in a male AKR/J mouse, have
een previously described [17]. Mice that died from
VHD or tumor progression were differentiated
rom one another on the basis of clinical symptoms
nd systemic autopsy ﬁndings. c
B&MT-Cell and DC Phenotyping
Peripheral blood was collected from early (day 28)
nd long-term (day 100) complete donor HSC chime-
as to assess the presence of donor BM-derived CD4
nd CD8 T cells, as well as CD4CD25 Treg cells,
y ﬂow cytometry. Peripheral blood leukocytes were
tained with the following panel of cell-surface mark-
rs: FITC–anti–H-2Kb, PE–anti-CD3 or PE–anti-
D25, PE–Cy5–anti-CD8, and allophycocyanin–an-
i-CD4. To assess the purity of isolated DCs, the cells
ere stained with a combination of FITC–anti-
D11c and PE–anti-CD11b. The samples were ana-
yzed on a Becton Dickinson FACSCalibur ﬂow cy-
ometer (San Jose, CA).
tatistics
Survival curves were compared by log-rank anal-
sis. Relative risk comparisons were performed by
sing Fisher exact tests. Body weight loss values were
ompared by using the t test. Signiﬁcance was deﬁned
s P  .05.
ESULTS
nduction of DLI-Induced GVHD after
reg Depletion Waned with Time
Previous studies from our group showed that sig-
iﬁcant lethal acute GVHD occurs after DLI in
HC-mismatched recipients until the fourth week
fter HSCT and that new thymus-derived donor Treg
ells are in large part responsible for suppressing the
VH reactivity at 4 weeks after HSCT [11]. How-
ver, it was unclear whether Treg cells continue to play
n important role at later time points. Therefore,
xperiments were performed to elucidate the kinetics
f Thy1 Treg cells in suppressing GVHD develop-
ent in longer-term chimeras. DLI given to MHC-
ismatched recipients at days 28, 35, 42, 49, or 70
esulted in little or no GVH-related mortality (Figure 1;
LI groups). In vivo depletion of Thy1 Treg cells by
reatment of BM chimeras with anti-Thy1.2 mAb im-
ediately before DLI resulted in severe and lethal
VHD when DLI was given at days 28, 35, and 42
Figure 1; anti-Thy1.2  DLI groups). In contrast,
fter Treg depletion, DLI induced relatively mild
VHD at day 49 and no GVHD at day 70. Flow
ytometric analysis of splenocytes from BM chimeras
t each DLI time point indicated that anti-Thy1.2
Ab treatment resulted in98% depletion of periph-
ral Thy1.2-expressing T cells (Figure 1).
he DLI-Induced GVL Effect Observed Early
Day 28) after HSCT Was Absent in Long-Term
Day 100) Complete Donor Chimeras
To study whether the DLI-induced GVL effect
orrelated with development of GVHD, early (day 28)
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4nd long-term (day 100) complete donor chimeras
ere treated with DLI and challenged with M2 leu-
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GVL and GVH Reactions After DLI
BLI-treated day 28 chimeras, 11 of 14 mice were
umor free for more than 70 days after challenge, with
ome long-term body weight loss (Figure 2C). Among
he 3 deaths that occurred in this group, 2 (days 14 and
9 after tumor challenge) resulted from tumor pro-
ression, whereas the third (day 56) was attributed to
VHD. Akin to non–DLI-treated controls (BM
ransplantation only), all DLI-treated day 100 chime-
as (12/12) died rapidly from tumor progression after
hallenge (Figure 2B), and corresponding acute body
eight loss was observed in these animals (Figure 2D).
epletion of CD25 Treg before DLI Failed to
estore the GVL Effect in Long-Term Complete
onor HSC Chimeras
Previous studies from our group revealed that
D4CD25 cells comprise the most potent Thy1
reg population in experimental DLI models [17,18].
hen donor-derived T cells in the peripheral blood
f day 28 and day 100 complete donor BM chimeras
ere phenotyped for CD3, CD4, CD8, and CD25
xpression, the percentage of CD25 cells within the
D4 population (ie, putative Treg cells) was relatively
igher in day 100 chimeras (9.7%-12.3%; n  3) than
n day 28 chimeras (5.7%-7.1%; n  3) or naive B6
ice (7.7%-9.5%; n 5), even though similar percent-
ges of CD3CD4 (15.5%-27.7% versus 17.4%-
8.8%) and CD3CD8 (5.7%-7.1% versus 5.7%-
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igure 2. The DLI-induced GVL effect in day 28 complete donor
) and body weight changes (C and D) are shown for DLI-treated o
himeras that were subsequently challenged with 103 AKR M2 leuk
hat were given HSCT only (no DLI or leukemia) served as contro
or the day 100 chimeras and 3 independent experiments for the da
otal numbers of mice in each group are shown in (C) and (D). BM.7%) were detected in day 28 and day 100 chimeras, 1
B&MTespectively. To determine whether the presence of
D4CD25 Treg contributed to the disappearance
f DLI-induced GVL in long-term chimeras, day 100
himeras were depleted of CD25 cells in vivo before
LI and subsequently challenged with M2 leukemia
ells 1 week after DLI (ie, day 107). CD25 cell
epletion failed to restore GVL reactivity (Figure 3).
ll anti-CD25/DLI–treated mice (n  11) died from
umor growth after challenge (Table 1), and the kinetics
f mortality in this group were similar to those of non–
D25-depleted mice given DLI (Figure 3A). Tumor
rogression was associated with cachexia (Figure 3B).
LI-Induced GVL Activity Occurred in Long-term
ixed HSC Chimeras without GVHD
To investigate whether the disappearance of a
LI-induced GVL effect in long-term complete do-
or chimeras is related to a deﬁciency of stimulatory
ost alloantigens, B6/AKR long-term mixed HSC chi-
eras were generated. By transplanting recipients
ith a mixture of donor and host BM at a 3:1 ratio,
5% donor hematopoietic chimerism could be achieved
data not shown). The mixed chimeras were given
DLI M2 group) or not given (M2 group) a DLI at
ay 100 after BM transplantation and then challenged
ith AKR M2 leukemia cells 1 week later (day 107). In
ontrast to complete chimeras, a robust GVL effect
as observed in mixed chimeras given DLI, with 13 of
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4fter tumor inoculation (Figure 4A). An absence of
ody weight loss in these mice correlated with an
bsence of GVH-associated mortality (Figure 4B), and
t was conﬁrmed that the 3 deaths were due to tumor
rogression. Long-term mixed chimeras not given a
LI were unable to resist the leukemia challenge, and
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igure 3. Depletion of CD25 Treg was unable to restore the
LI-induced GVL effect in day 100 complete donor HSC chime-
as. Survival (A) and body weight changes (B) are shown for day 100
omplete donor chimeras treated or not treated with in vivo–
epleting anti-CD25 mAb and/or DLI and then challenged with
03 AKR M2 leukemia cells 1 week later (day 107). The data for the
nti-CD25  M2 and anti-CD25  DLI  M2 experimental
roups represent the combined results of 4 independent experi-
ents. Each group was included in at least 2 of the 4 experiments,
hich were all completed within a 9-month time period. The
urvival curves for the BM transplantation only, M2, and DLIM2
roups are the same as in Figure 2, and they are shown simply to
rovide comparative survival data for the anti-CD25  M2 and
nti-CD25  DLI  M2 experimental groups. The total numbers
f mice in each group are shown in (B) BMT, bone marrow
ransplantation.
able 1. Outcomes for DLI-Treated and Tumor-Challenged Day 100
Group Anti-CD25 Host DCs
1 No No 1
2 No 2.5  106 8
3 No 5.0  106
4 Yes No 1
5 Yes 2.5  106 6
6 Yes 5.0  106 1
These data were obtained from the experiments in Figures 3, 5, a
MST, median survival time.
As analyzed by using Fisher exact tests, the relative risk of dying fr
and the relative risk of dying from GVHD was signiﬁcantly gre
survival curves for groups: 1 vs. 2, P  .019; 1 vs. 3, P  .0014;
2 vs. 5, P  NS; 3 vs. 6, P  NS.
02ll mice in this group died between 15 and 30 days
fter tumor challenge (Figure 4).
ost-Type DCs Coinfused with DLI Partially
estored GVL and GVH Effects in Long-Term
omplete Donor Chimeras
Results in previous experiments suggested that the
ersistence of host-type APCs in day 100 mixed HSC
himeras facilitated a GVL effect in DLI-treated an-
mals and that a lack of host APCs in day 100 complete
onor chimeras was responsible for the absence of a
e Donor Chimeras
lity* MST (d)† Causes of Death (n)
2/12) 15 Tumor (12), GVHD (0)
/11) 27 Tumor (9), GVHD (0)‡
/10) 38 Tumor (1), GVHD (7)
1/11) 15 Tumor (11), GVHD (0)
/12) 25 Tumor (2), GVHD (6)‡
0/10) 41 Tumor (0), GVHD (10)
or was signiﬁcantly greater in group 2 than in group 5 (P  .003),
group 5 than in group 2 (P  .014). Log-rank comparisons of the
, P  NS (not signiﬁcant); 4 vs. 5, P  .00488; 4 vs. 6, P  .0022;
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BVL effect. To address this further, host-type DCs
2.5 or 5  106 per mouse) were coinfused with a DLI
nto day 100 chimeras to determine whether a DLI-
nduced GVL effect could be restored by infusion of
ost APCs. Although coadministration of 2.5  106
Cs with the DLI did not result in signiﬁcantly better
urvival after tumor challenge as compared with non–
LI-treated chimeras (Figure 5A), the median sur-
ival time in DLI-treated mice was increased from 15
o 27 days (Table 1, groups 1 and 2). When the DC
ose was increased to 5  106 cells, DLI coadminis-
ration resulted in a signiﬁcant survival beneﬁt as com-
ared with non–DLI-treated chimeras (Figure 5B),
nd the median survival time in DLI-treated mice was
urther increased to 38 days (Table 1, group 3). It is
nteresting to note that although all deaths in the
himeras given 2.5  106 DCs and DLI (n  9) were
ttributed to tumor progression, most deaths in chi-
eras given 5  106 DCs and DLI (7 of 8 deaths)
ere attributed to GVHD (Table 1). Signiﬁcantly
ncreased body weight loss in the long-term chimeras
iven 5 106 DCs and DLI (DLIDCM2 group;
igure 5D) as compared with chimeras not given DLI
DLI  M2 group; Figure 5D) correlated with the
ncreased GVH reactivity. However, no enhancement
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igure 5. Infusion of host-type DCs partially restored DLI-induce
A and B) and body weight changes (C and D) are shown for day 10
) host-type DCs with or without DLI followed by challenge with
esults of 3 independent experiments. Each group was included in
ime period. The total numbers of mice in each group are shown in (
roup is the same as that shown in Figure 2B, and it is shown to pro
ice given 5  106 DCs (D), body weight loss in the DLI  DC 
ays 7 and 14 after tumor challenge, as indicated by the asterisks,f GVHD was seen in DLI-treated day 28 complete i
B&MTonor chimeras coinfused with 5  106 fresh host-
ype DCs (Figure 6).
ong-Term Chimeras Depleted of CD25 Treg
ells before Coinfusion of Host DCs and
LI Had Increased GVL Reactivity at the
xpense of GVHD
We next examined whether DLI-mediated GVH/
VL reactions initiated by host DC administration
re inﬂuenced by donor CD25 Treg cells. To address
his, day 100 complete donor chimeras were treated
ith 2 injections of anti-CD25 mAb at days 93 and 96
fter HSCT to deplete CD25 cells in vivo. CD25-
epleted or -nondepleted mice were treated either
ith DCs alone (2.5 or 5 106 cells) or DCs plus DLI
t day 100, and all mice were subsequently challenged
ith 103 AKR M2 leukemia cells at day 107. In vivo
epletion of CD25 cells before DLI (no host DCs)
ad no effect on GVL reactivity (Table 1, group 1
ersus 4). As shown in Figure 7A and 7B, DLI/DC
oadministration modestly increased 70-day survival
s compared with chimeras given DCs without DLI,
ut the increases in survival were not signiﬁcant, and
epletion of CD25 cells had no effect on survival.
owever, depletion of CD25 cells did signiﬁcantly
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4Table 1, group 2 versus 5; P  .003), but any survival
eneﬁt was negated by signiﬁcantly increased GVH
eactivity in these animals (P  .014).
ISCUSSION
In early animal studies, immune-suppressive/reg-
latory cells were implicated as playing a role in the
uppression of GVH reactivity after DLI [10]. Subse-
uent studies from our group and others demon-
trated that various types of donor-derived cells and
ven residual host cells, including non-T cells, may be
nvolved in regulating development of DLI-induced
VHD [11,18-24].However, donorThy1CD4CD25
ells seem to be the most potent Treg population
ccording to studies in our laboratory examining the
elationship of DLI-induced GVHD and deﬁciency of
articular donor-derived T-cell subsets [11,18]. DLI
s typically administered weeks or months after HSCT
o treat tumor relapse in humans [4]. Therefore, it is
onceivable that donor reconstitution of the host thy-
us has occurred in some DLI-treated patients and
hat donor-derived Treg cells play a role in blunting
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igure 6. Infusion of host-type DCs did not enhance DLI-induced
VHD in short-term day 28 complete donor chimeras. Survival (A)
nd body weight changes (B) are shown for day 28 complete donor
himeras given DLI with or without 5  106 host-type DCs.
ontrols that received BM transplantation only were included in
hese experiments. The data represent the combined results of 3
ndependent experiments. Each group was included in at least 2 of
he 3 experiments, and the total numbers of mice in each group are
hown in (B). The survival curve for the BM transplantation–only
roup is the same as that shown in Figure 2A, and it is shown to
rovide comparative survival data for the other experimental
roups. BMT, bone marrow transplantation.LI-induced GVH reactivity. This may in part ac- W
04ount for the ability to give patients relatively large
umbers of donor T cells with less severe GVHD
han would be anticipated if similar numbers of T cells
ere given at the time of HSCT.
In the experiments shown in Figure 1, we ex-
ended our previous ﬁndings in day 28 complete do-
or HSC chimeras to examine the importance of
hy1 Treg cells at later time points. We conﬁrmed
ur previous observations in day 28 chimeras demon-
trating suppression of DLI-induced GVH reactivity
y Thy1 regulatory cells, and depletion of donor
hy1 cells in day 35 and day 42 chimeras similarly
esulted in lethal acute GVHD, thus indicating that
hy1 Treg cells still played an important role in
uppressing DLI-induced GVH reactivity at these
ater time points. However, by day 49 after HSCT,
he role of Thy1 Treg cells was no longer evident.
his could be due to turnover of APCs from host to
onor type during this time period, thus resulting in
ecreased activation of alloreactive T cells given as
LI. The presence of host-type APCs has been
hown by others to be an absolute requirement for
he induction of GVHD in murine HSCT models
12,15,25,26], and DLI in humans and dogs with
ixed chimerism has resulted in GVHD [27,28].
lternatively, it has been suggested that the persis-
ence of Treg cells requires the ongoing presence of
ognate Ags [29]. Thus, it is possible that Treg cells
peciﬁc for host allo-Ags decrease in frequency as
PCs turn over. However, the GVH reactivity in-
uced in our long-term complete donor chimeras by
oadministration of host-type DCs and DLI seemed
o be regulated in part by CD25 Treg cells (Table 1),
hus indicating that these cells persisted in the long-
erm chimeras. CD4CD25 Treg cells have been
sed to effectively prevent or treat GVHD after
SCT or DLI [18,19,30-34]. A potential problem
ith this approach is that accumulating evidence has
uggested that CD4CD25 Treg cells can promote
umor growth/progression [35-38]. Therefore, deple-
ion of CD4CD25 cells may have a synergistic
eneﬁt with DLI therapy to clear tumor cells, partic-
larly when the DLI-induced anti-tumor response
lone is too weak to completely eradicate the tumor
ells.
An absence of GVHD in DLI-treated long-term
omplete chimeras after Thy1 Treg cell depletion
Figure 1E) correlated with an absence of GVL reac-
ivity in these animals (Figure 2B). These results are
onsistent with ﬁndings from other investigators who
howed that GVL reactivity after DLI was absent in
HC-matched (day 84 after transplantation) or -mis-
atched (day 56 after transplantation) HSCT models,
s well as in complete donor chimeras that had con-
erted from a state of mixed chimerism to complete
himerism several weeks after DLI treatment [14-16].
e also observed a robust DLI-induced GVL effect
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Bn day 28 complete donor chimeras (Figure 2A) and in
ay 100 mixed chimeras (Figure 4A). Mapara et al.
15,16] similarly reported DLI-induced GVL reactiv-
ty without GVHD in day 56 mixed chimeras and a
uperior GVL effect in mixed chimeras as compared
ith complete donor chimeras. Other data have indi-
ated that GVH reactions in mixed chimeric mice
fter DLI may be conﬁned to the lymphohematopoi-
tic tissues, which may account for the absence of
LI-induced GVHD in these animals [39]. Clinically,
cute myeloid leukemia patients have responded bet-
er to DLI therapy than patients with acute lympho-
ytic leukemia, possibly as a result of direct tumor Ag
resentation by myeloid leukemia cells that express
mmune costimulatory molecules [1]. It is interesting
o note that we found that deﬁcient GVL reactivity in
ong-term complete HSC chimeras could be partially
estored by coadministration of host-type DCs and
LI (Figure 5A and B), but the increased GVL effect
ccurred at the expense of more GVHD (Table 1).
his suggests the involvement of common target Ags.
owever, it needs to be pointed out that our studies
id not distinguish whether GVHD in the long-term
himeras actually involved tissue inﬁltration by donor
cells or was due to a cytokine storm. Clinically, the
VL effects of DLI therapy have also been closely
ssociated with GVHD [1-5]. Thus, separation of
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igure 7. Depletion of CD25 cells increased GVH/GVL reactivi
A and B) and body weight changes (C and D) are shown for CD25
06 (A and C) or 5  106 (B and D) host-type DCs with or without
ata for the anti-CD25–treated groups represent the combined res
f the 3 experiments that were all performed within a 6-month tim
D). Survival curves for the DC M2 and DLI  DC M2 group
omparative survival data for the other experimental groups.VL from GVH may be complicated because of the p
B&MTature of the target Ags. Our experimental results
eem to favor the hypothesis that turnover of APCs
rom host type to donor type results in diminished
VH and GVL reactivities after DLI therapy, which
s consistent with ﬁndings from other research groups
25,26]. Moreover, the absolute requirement for host-
ype APCs to elicit a GVL effect was elegantly dem-
nstrated by the work of Mapara et al. [15] showing
hat GVL was robust when host-type DCs expressed
HC class I Ags but absent when host-type DCs in
ixed chimeric mice were deﬁcient in MHC class I. In
ne clinical study involving the use of prophylactic
LI to treat tumors after T cell–depleted BM trans-
lantation, myeloablated patients were shown to tol-
rate higher dose of T cells and develop less severe
VHD when DLI was performed at 45 days instead
f 30 days after transplantation [40]. However, DLI
as mostly been used to treat residual or relapsed
alignancies, and there are no conclusive data regard-
ng the timing of administration and DLI-induced
oxicity and/or GVL efﬁcacy. Furthermore, beneﬁts
rom DLI treatment are complicated by patient het-
rogeneity, tumor burden, the T-cell dose(s), and
ther therapies [1-5]. In practice, restoration of GVL/
VH activities by coinfusion of fresh host-type DCs
ould be difﬁcult in humans because the DCs would
eed to be generated and cryopreserved before trans-
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4Data in Figure 4, as well as results from other
nvestigators, have suggested that a state of mixed
himerism is important to facilitate a GVL effect with-
ut signiﬁcant GVHD after DLI therapy in long-term
urine chimeras [15,16]. Nonmyeloablative condition-
ng regimens can facilitate the establishment of mixed
himerism with less toxicity than myeloablative regi-
ens, but mixed chimerism is associated with a higher
isk for tumor relapse because of the development of
onor/host T-cell tolerance [41]. Fortunately, antitu-
or responses have been effectively generated after
LI therapy in both myeloablative and nonmyeloab-
ative settings [41]. Unlike mice, mixed chimeric pa-
ients frequently develop GVHD after DLI, and the
ncidence and severity of GVHD in these patients has
een lower than or equivalent to that of complete
himeric patients [27,42]. In contrast to the results
rom complete chimeric patients, no signiﬁcant differ-
nces in GVHD development were observed in mixed
himeric patients whether DLI was performed within
he ﬁrst 100 days after transplantation or beyond 180
ays after transplantation [27,40]. These observations
ould be explained by the continuous presence of host
PCs in mixed chimeric patients. Studies are needed
o address the discrepancy between the ﬁndings in
ice and humans, and a thorough clinical analysis is
eeded to examine the relationship between DLI-
nduced GVL/GVHD and the timing of DLI, as well
s the relationship of DLI-induced GVL and GVHD
n patients with mixed multilineage chimerism.
In summary, a state of mixed chimerism was su-
erior to complete donor chimerism, because preser-
ation of host-type APCs seemed to be essential for
nitiating DLI-induced GVL/GVH reactions in our
tudies. These results are consistent with previous
ndings by other investigators [15]. Infusion of host-
ype DCs partially restored a DLI-induced GVL ef-
ect in long-term complete chimeras, but restoration
f GVL reactivity was accompanied with an increased
isk for GVHD. Our data indicate that donor-derived
reg cells can regulate DLI-induced GVL and GVH
eactions in both early and long-term complete donor
himeras. The role of donor BM–derived Treg cells in
ur mixed chimeric DLI model is under investigation,
nd we are interested in testing whether modulating
he functional activity of Treg cells can optimize GVL
eactions in mixed chimeras.
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